Recruiting
Phase 3

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

Sponsor:

Keryx Biopharmaceuticals

Code:

NCT04523727

Conditions

Hyperphosphatemia Related to Chronic Kidney Disease

Eligibility Criteria

Sex: All

Age: 6 - 16

Healthy Volunteers: Not accepted

Interventions

ferric citrate

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information